Omixon & PIRCHE® collaborate on Epitope Determination with NGS

17/09/2018

Global molecular diagnostics company Omixon, headquartered in Budapest, and technology company PIRCHE AG, headquartered in Berlin announce a collaboration to deliver the first integrated epitope determination and matching service that leverages whole gene consensus sequences assembled from NGS data of the HLA region. For the first time, fully characterized...

Benefits of HLA Typing by NGS for Organ Transplantation

03/07/2018

Mette Christiansen (Aarhus University Hospital) was focusing on the benefits of HLA typing by NGS for organ transplantation during her User Group Meeting talk at the EFI 2018 conference. The presentation includes slides of the use of high-resolution (vs. low-resolution) typings in solid organ transplantation. Download the full presentation...

Omixon Educative Series: HLA – Basic Immunological Roles

16/03/2018

Learn more about the role of the human leukocyte antigen (HLA) system in and beyond transplantation! Please find the first part of our HLA Educative Series that targets a wide range of knowledge levels. We start with their basic immunology that will be followed by their roles in transplantation,...

One Donor Can Save Eight Lives

14/02/2018

You, or anyone you know would need to have an organ transplant, would be one out of those 116,000 individuals from the US national transplant waiting list. In fact, 10 people are added to the list in every single minute. Despite improvements in the organ registration systems and in...

Omixon and World Fusion Extend Their Partnership in Japan

27/10/2017

World Fusion is a leading bioinformatics company in Japan that focuses on therapeutic target discovery, gene expression analysis, and variant analysis. Their highly skilled and motivated team has been the successful marketer of Omixon’s software products since 2014, and we are pleased to announce World Fusion as a distributor...